Key Details
Annual ROE
-149.61%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 09, 2023Recent annual earnings:
Mar 15, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
18 Apr '23 HC Wainwright & Co.
Neutral30 Mar '23 Mizuho
Neutral30 Mar '23 HC Wainwright & Co.
Buy15 Nov '22 SVB Leerink
Market Perform15 Nov '22 Mizuho
Neutral15 Nov '22 HC Wainwright & Co.
Buy10 Oct '22 SVB Leerink
Outperform21 Sept '22 HC Wainwright & Co.
Buy31 Aug '22 Ladenburg Thalmann
Buy25 Aug '22 JonesTrading
BuyScreeners with STSA included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Satsuma Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
STSA
prnewswire.com30 October 2024
DURHAM, N.C. , Oct. 30, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
STSA
prnewswire.com13 June 2024
DURHAM, N.C. , June 13, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.
FAQ
- What is the primary business of Satsuma Pharmaceuticals?
- What is the ticker symbol for Satsuma Pharmaceuticals?
- Does Satsuma Pharmaceuticals pay dividends?
- What sector is Satsuma Pharmaceuticals in?
- What industry is Satsuma Pharmaceuticals in?
- What country is Satsuma Pharmaceuticals based in?
- When did Satsuma Pharmaceuticals go public?
- Is Satsuma Pharmaceuticals in the S&P 500?
- Is Satsuma Pharmaceuticals in the NASDAQ 100?
- Is Satsuma Pharmaceuticals in the Dow Jones?
- When was Satsuma Pharmaceuticals's last earnings report?
- When does Satsuma Pharmaceuticals report earnings?
- Should I buy Satsuma Pharmaceuticals stock now?
What is the primary business of Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
What is the ticker symbol for Satsuma Pharmaceuticals?
The ticker symbol for Satsuma Pharmaceuticals is NASDAQ:STSA
Does Satsuma Pharmaceuticals pay dividends?
No, Satsuma Pharmaceuticals does not pay dividends
What sector is Satsuma Pharmaceuticals in?
Satsuma Pharmaceuticals is in the Healthcare sector
What industry is Satsuma Pharmaceuticals in?
Satsuma Pharmaceuticals is in the Biotechnology industry
What country is Satsuma Pharmaceuticals based in?
Satsuma Pharmaceuticals is headquartered in United States
When did Satsuma Pharmaceuticals go public?
Satsuma Pharmaceuticals's initial public offering (IPO) was on 13 September 2019
Is Satsuma Pharmaceuticals in the S&P 500?
No, Satsuma Pharmaceuticals is not included in the S&P 500 index
Is Satsuma Pharmaceuticals in the NASDAQ 100?
No, Satsuma Pharmaceuticals is not included in the NASDAQ 100 index
Is Satsuma Pharmaceuticals in the Dow Jones?
No, Satsuma Pharmaceuticals is not included in the Dow Jones index
When was Satsuma Pharmaceuticals's last earnings report?
Satsuma Pharmaceuticals's most recent earnings report was on 9 August 2023
When does Satsuma Pharmaceuticals report earnings?
The date for Satsuma Pharmaceuticals's next earnings report has not been announced yet
Should I buy Satsuma Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions